BeiGene Ltd (HK:6160) has released an update.
BeiGene, Ltd., a biopharmaceutical company, has published its quarterly report (Form 10-Q) as required by the U.S. Securities and Exchange Commission for the period ending June 30, 2024. The report details the company’s shares and their respective exchanges, including American Depositary Shares on the Nasdaq and ordinary shares on the Hong Kong Stock Exchange as well as the Science and Technology Innovation Board of the Shanghai Stock Exchange. Investors and stakeholders are encouraged to review the document, which is accessible on the SEC’s website.
For further insights into HK:6160 stock, check out TipRanks’ Stock Analysis page.
